Kuyesa Kwatsopano Kwachipatala kwa Khansa ya Prostate ya Metastatic Castration-Resistant Prostate

Written by mkonzi

Kampani yopanga mankhwala ya ESSA Pharma Inc., yomwe imayang'ana kwambiri pakupanga mankhwala atsopano ochizira khansa ya prostate, lero yalengeza wodwala woyamba kuyesedwa mu kafukufuku wothandizidwa ndi kampani wa Phase 1/2 kuti awunikire chitetezo, kulolera komanso kuthandizira koyambirira kwa ESSA. lead product candidate, EPI-7386, first in-class N-terminal domain androgen receptor inhibitor, kuphatikiza ndi Astellas Pharma Inc.'s ndi Pfizer Inc.'s ligand-binding domain androgen receptor inhibitor, enzalutamide, mwa odwala omwe ali ndi vuto metastatic castration-resistant khansa ya prostate.

Sangalalani, PDF ndi Imelo

"Kuyambika kwa mayesero ophatikizana ndi Astellas ndi nthawi yamadzi kwa ESSA pamene tikufufuza phindu lachipatala lomwe lingathe kulepheretsa kulandira androgen kupyolera mu njira ziwiri zodziimira pa chithandizo cha odwala omwe ali ndi mCRPC omwe sanalandire chithandizo ndi antiandrogen ya m'badwo wachiwiri. mankhwala,” anatero Dr. David. R. Parkinson, Chief Executive Officer, ESSA Pharma Inc. "Kuphatikiza machiritso athu awiri nthawi imodzi kumayang'ana mbali zonse za androgen receptor. M'mawonekedwe a preclinical, tawona kuti kuphatikiza EPI-7386 ndi antiandrogens omwe alipo panopa kungayambitse kulepheretsa kwakukulu kwa androgen biology. Mayesero a Gawo 1/2wa ndi oyamba mwa maphunziro azachipatala kuti aunike EPI-7386 kuphatikiza njira zochiritsira zaposachedwa za antiandrogen mwa odwala omwe ali ndi mCRPC, ndi mayeso ophatikiza a Phase 1/2 omwe akuyembekezeka kuyamba mu 2022.

Chiyeso chachipatala cha Phase 1/2 (NCT05075577) chimayamba ndi gawo loyamba pomwe milingo yamankhwala aliwonse imasinthidwa ndikutsatiridwa ndi gawo lachiwiri pomwe wothandizira mmodzi enzalutamide amafaniziridwa ndi kuphatikiza kwa enzalutamide ndi EPI-1. Phunziro la gawo la 2 likuyembekezeredwa kuti lilembetse odwala a 7386 mCRPC omwe sanalandire chithandizo cham'badwo wachiwiri wa antiandrogen. Cholinga cha gawo 1 la phunziroli ndikuwunika chitetezo ndi kulekerera kwa kuphatikiza kwa mankhwalawa ndikukhazikitsa mlingo wovomerezeka wa gawo 30 wa EPI-1 ndi enzalutamide ukaphatikizidwa. Phunziro la gawo la 2 likuyembekezeka kulembetsa odwala a 7386 mCRPC omwe sanalandire chithandizo cham'badwo wachiwiri wa antiandrogen. Cholinga cha gawo lachiwiri la phunziroli ndikuwunika chitetezo, kulekerera ndi ntchito ya antitumor ya EPI-2 kuphatikiza ndi mlingo wokhazikika wa enzalutamide poyerekeza ndi enzalutamide ngati wothandizira m'modzi.

Sangalalani, PDF ndi Imelo
Palibe ma tag apa positi.

Ponena za wolemba

mkonzi

Mkonzi wamkulu wa eTurboNew ndi Linda Hohnholz. Amakhala ku eTN HQ ku Honolulu, Hawaii.

Siyani Comment

eTurboNews | | Mbiri ya TravelIndustry